Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial

Naim Alkhouri,Robert Herring,Heidi Kabler,Zeid Kayali,Tarek Hassanein,Anita Kohli,Ryan S Huss,Yanni Zhu,Andrew N Billin,Lars Holm Damgaard,Kristine Buchholtz,Mette Skalshøi Kjær,Clare Balendran,Robert P Myers,Rohit Loomba,Mazen Noureddin

Journal of Hepatology（2022）

引用 60|浏览22

暂无评分

摘要

•Combining therapies with complementary mechanisms may be beneficial in patients with NASH.•In a phase II trial in 108 patients with NASH, semaglutide alone or in combination with cilofexor and/or firsocostat was well tolerated.•Combinations resulted in greater improvements in liver steatosis, liver biochemistry, and non-invasive tests of fibrosis.

查看译文

关键词

semaglutide,firsocostat,cilofexor,non-alcoholic steatohepatitis,NASH,fibrosis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要